Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene
An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated With Calcipotriene Ointment
Sponsor: Sienna Biopharmaceuticals
A PHASE2 clinical study on Pruritus and Psoriasis, this trial is completed. The trial is conducted by Sienna Biopharmaceuticals and has accumulated 13 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE2
-
Mar 2019 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 8 earlier versions
-
Feb 2019 — Mar 2019 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Oct 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE2
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Mar 2018 — May 2018 [monthly]
Recruiting PHASE2
First recorded
Feb 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sienna Biopharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .